Walleye Capital’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.2M Buy
+4,075
New +$1.07M ﹤0.01% 3290
2026
Q2
– Sell
-1,932
Closed -$333K – 4797
2026
Q1
$333K Sell
1,932
-249,189
-99% -$46.2M ﹤0.01% 2990
2025
Q4
$50.1M Buy
251,121
+25,121
+11% +$4.56M 0.15% 63
2025
Q3
$35.4M Buy
226,000
+221,782
+5,258% +$35.2M 0.13% 109
2025
Q2
$640K Buy
+4,218
New +$562K ﹤0.01% 2427
2024
Q3
– Sell
-63,913
Closed -$13.3M – 5383
2024
Q2
$13.2M Buy
63,913
+63,778
+47,243% +$14.5M 0.02% 593
2024
Q1
$36.6K Buy
+135
New +$32.2K ﹤0.01% 4772
2023
Q4
– Sell
-8,561
Closed -$1.68M – 5021
2023
Q3
$1.68M Buy
+8,561
New +$1.76M ﹤0.01% 1872
2022
Q4
– Sell
-28,386
Closed -$5.59M – 3257
2022
Q3
$5.59M Buy
28,386
+11,427
+67% +$2.47M 0.11% 209
2022
Q2
$3.63M Sell
16,959
-27,364
-62% -$6.69M 0.1% 228
2022
Q1
$12.6M Buy
44,323
+13,642
+44% +$4.21M 0.34% 51
2021
Q4
$11.6M Buy
30,681
+29,744
+3,174% +$11.6M 0.36% 52
2021
Q3
$387K Buy
+937
New +$389K 0.01% 898
2020
Q1
– Sell
-1,140
Closed -$175K – 1056
2019
Q4
$175K Buy
1,140
+1,090
+2,180% +$151K 0.01% 1173
2019
Q3
$7K Hold
50
– – ﹤0.01% 1788
2019
Q2
$7K Sell
50
-1,342
-96% -$182K ﹤0.01% 1614
2019
Q1
$202K Buy
+1,392
New +$183K 0.03% 778

Other funds holding CRL

Walleye Capital's CRL Position: Q3 2026 in Review

Walleye Capital opened a new position in Charles River Laboratories (CRL) in Q3 2026: 4,075 shares worth $1.2M. The stake represents ﹤0.01% of the portfolio and ranks #3290 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CRL as recently as Q1 2026.

Walleye Capital first reported a position in CRL in Q1 2019 and has held it in 17 quarters since. The position peaked at $50.1M in Q4 2025. 639 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Walleye Capital held 4,075 shares of Charles River Laboratories worth $1.2M as of Q3 2026.
  • Charles River Laboratories was a new Walleye Capital position in Q3 2026.
  • Charles River Laboratories made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3290 holding.
  • Walleye Capital first reported a position in Charles River Laboratories in Q1 2019 and has held it in 17 quarters since.
  • Walleye Capital's Charles River Laboratories position peaked at $50.1M in Q4 2025.
  • 639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.